Business Description
Daiken Biomedical Co Ltd
ISIN : TW0007780009
Compare
Compare
Traded in other countries / regions
7780.Taiwan Index Membership
TSEC Weighted Index IPO Date
2024-10-28Description
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 44.56 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.21 | |||||
Interest Coverage | 192.53 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.78 | |||||
Beneish M-Score | -1.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -63.2 | |||||
3-Year EBITDA Growth Rate | -55.2 | |||||
3-Year EPS without NRI Growth Rate | -55.5 | |||||
3-Year FCF Growth Rate | -46.9 | |||||
3-Year Book Growth Rate | 160.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.59 | |||||
9-Day RSI | 35.26 | |||||
14-Day RSI | 38.38 | |||||
3-1 Month Momentum % | -8.7 | |||||
6-1 Month Momentum % | -16.21 | |||||
12-1 Month Momentum % | -11.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.75 | |||||
Quick Ratio | 4.33 | |||||
Cash Ratio | 4.17 | |||||
Days Inventory | 183.61 | |||||
Days Sales Outstanding | 20.77 | |||||
Days Payable | 59.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 8.1 | |||||
Dividend Payout Ratio | 2.51 | |||||
Forward Dividend Yield % | 8.1 | |||||
5-Year Yield-on-Cost % | 8.05 | |||||
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | 7.85 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.79 | |||||
Operating Margin % | 18.02 | |||||
Net Margin % | 19.44 | |||||
EBITDA Margin % | 25.53 | |||||
FCF Margin % | 11.95 | |||||
OCF Margin % | 12.01 | |||||
ROE % | 9.53 | |||||
ROA % | 8.32 | |||||
ROIC % | 113.22 | |||||
3-Year ROIIC % | 60.83 | |||||
ROC (Joel Greenblatt) % | 366.58 | |||||
ROCE % | 12.28 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.82 | |||||
Forward PE Ratio | 16.29 | |||||
PE Ratio without NRI | 29.82 | |||||
PS Ratio | 5.76 | |||||
PB Ratio | 2.71 | |||||
Price-to-Tangible-Book | 2.72 | |||||
Price-to-Free-Cash-Flow | 49.25 | |||||
Price-to-Operating-Cash-Flow | 48.95 | |||||
EV-to-EBIT | 14.65 | |||||
EV-to-EBITDA | 14.46 | |||||
EV-to-Revenue | 3.68 | |||||
EV-to-FCF | 31.81 | |||||
Price-to-Graham-Number | 1.9 | |||||
| Price-to-Net-Current-Asset-Value | 2.82 | |||||
| Price-to-Net-Cash | 3.34 | |||||
Earnings Yield (Greenblatt) % | 6.83 | |||||
FCF Yield % | 1.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daiken Biomedical Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 2,185.621 | ||
| EPS (TTM) (NT$) | 0.55 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 68.61 | ||
| 14-Day RSI | 38.38 | ||
| 14-Day ATR (NT$) | 0.249993 | ||
| 20-Day SMA (NT$) | 16.7725 | ||
| 12-1 Month Momentum % | -11.58 | ||
| 52-Week Range (NT$) | 16 - 29.4 | ||
| Shares Outstanding (Mil) | 805.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daiken Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daiken Biomedical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 0.116589 Cash Dividend | 2026-09-03 | 17.05 (+1.19%) | ||
| TWD 0.893402 Cash Dividend | 2026-06-22 | 19.20 (-1.03%) | ||
| 10:1 Stock Split | 2026-01-09 | 18.50 (+1.09%) | ||
| TWD 0.084786 Cash Dividend | 2025-11-24 | 18.10 (+0.56%) | ||
| TWD 0.245101 Cash Dividend | 2025-08-25 | 31.95 (+0.00%) | ||
| TWD 0.157497 Cash Dividend | 2025-07-22 | 30.00 (+9.09%) | ||
| TWD 0.331670 Cash Dividend | 2025-06-17 | 17.40 (-1.14%) | ||
| TWD 0.071613 Cash Dividend | 2025-02-26 | 17.55 (+0.29%) |
Show
Entries
Daiken Biomedical Co Ltd Frequently Asked Questions
What is Daiken Biomedical Co Ltd(TPE:7780)'s stock price today?
The current price of TPE:7780 is NT$16.40. The 52 week high of TPE:7780 is NT$29.40 and 52 week low is NT$16.00.
When is next earnings date of Daiken Biomedical Co Ltd(TPE:7780)?
The next earnings date of Daiken Biomedical Co Ltd(TPE:7780) is .
Does Daiken Biomedical Co Ltd(TPE:7780) pay dividends? If so, how much?
The Dividend Yield %  of Daiken Biomedical Co Ltd(TPE:7780) is 8.1% (As of Today), Highest Dividend Payout Ratio of Daiken Biomedical Co Ltd(TPE:7780) was 17.47. The lowest was 2.51. And the median was 17.47. The  Forward Dividend Yield % of Daiken Biomedical Co Ltd(TPE:7780) is 8.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers